Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
Erik A. Imel(Indiana University – Purdue University Indianapolis), Anthony A. Portale(University of California, San Francisco), Noriyuki Namba(Osaka Hospital), Hae Il Cheong(Seoul National University Children's Hospital), Andrew Biggin(Children's Hospital at Westmead), Farzana Perwad(University of California, San Francisco), Etienne Sochett(Hospital for Sick Children), Alison Skrinar, Michael P. Whyte(Shriners Hospitals for Children - St. Louis), Craig F. Munns(Children's Medical Research Institute), Ola Nilsson(Karolinska University Hospital), Koji Muroya(TEPCO (Japan)), Leanne M. Ward(Children's Hospital of Eastern Ontario), Raja Padidela(University of Groningen), Gary S. Gottesman(Shriners Hospitals for Children - St. Louis), Javier San Martín(Universidad Nacional de Educación a Distancia), Chao-Yin Chen(University of Groningen), Pisit Pitukcheewanont(Children's Hospital of Los Angeles), Meng Mao(Guiyang Medical University), Hiroyuki Tanaka(Okayama Saiseikai General Hospital), Jill H. Simmons(Vanderbilt University), Wolfgang Högler(Johannes Kepler University of Linz), Francis H. Glorieux(Shriners Hospitals for Children - Canada)
Cited by 375
Related Papers
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Global Consensus Recommendations on Prevention and Management of Nutritional Rickets
|The Journal of Clinical Endocrinology & Metabolism|2016|1.1k